EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Yap methylation‐induced FGL1 expression suppresses anti‐tumor immunity and promotes tumor progression in KRAS ‐driven lung adenocarcinoma

Ji Jiang, Pengfei Ye, Ningning Sun, Weihua Zhu, Mei Yang, Manman Yu, Jingjing Yu, Hui Zhang, Zijie Gao, Ningjie Zhang, Shijie Guo, Yuru Ji und 10 weitere

Cancer Communications · 2024

DOI: 10.1002/cac2.12609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2024. Verfasst von Ji Jiang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, Anhui Medical University; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui C…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Adenocarcinoma of Lung, Lung Neoplasms, YAP-Signaling Proteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China Youth Project, Basic and Clinical Collaboration Enhancement Program of Anhui Medical University, The Research Program for Higher Education Institutions in Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite significant strides in lung cancer immunotherapy, the response rates for Kirsten rat sarcoma viral oncogene homolog ( KRAS )‐driven lung adenocarcinoma (LUAD) patients remain limited. Fibrinogen‐like protein 1 (FGL1) is a newly identified immune checkpoint target, and the study of related resistance mechanisms is crucial for improving the treatment outcomes of LUAD patients. This study aimed to elucidate the potential mechanism by which FGL1 regulates the tumor microenvironment in KRAS ‐mutated cancer.

Methods

The expression levels of FGL1 and SET1 histone methyltransferase (SET1A) in lung cancer were assessed using public databases and clinical samples. Lentiviruses were constructed for transduction to overexpress or silence FGL1 in lung cancer cells and mouse models. The effects of FGL1 and Yes‐associated protein (Yap) on the immunoreactivity of cytotoxic T cells in tumor tissues were evaluated using immunofluorescence staining and flow cytometry. Chromatin immunoprecipitation and dual luciferase reporter assays were used to study the SET1A‐directed transcriptional program.

Results

Upregulation of FGL1 expression in KRAS ‐mutated cancer was inversely correlated with the infiltration of CD8 + T cells. Mechanistically, KRAS activated extracellular signal‐regulated kinase 1/2 (ERK1/2), which subsequently phosphorylated SET1A and increased its stability and nuclear localization. SET1A‐mediated methylation of Yap led to Yap sequestration in the nucleus, thereby promoting Yap‐induced transcription of FGL1 and immune evasion in KRAS ‐driven LUAD. Notably, dual blockade of programmed cell death‐1 (PD‐1) and FGL1 further increased the therapeutic efficacy of anti‐PD‐1 immunotherapy in LUAD patients.

Conclusion

FGL1 could be used as a diagnostic biomarker of KRAS ‐mutated lung cancer, and targeting the Yap‐FGL1 axis could increase the efficacy of anti‐PD‐1 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Adenocarcinoma of LungLung NeoplasmsYAP-Signaling ProteinsHumansAnimalsMiceCell Line, TumorTumor MicroenvironmentAdaptor Proteins, Signal TransducingDisease ProgressionGene Expression Regulation, NeoplasticMethylationTranscription Factors

Stichwörter der Autor:innen

FGL1KRAS‐drivenSET1AYapimmune evasionlung adenocarcinomamethylation

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanYAP-Signaling ProteinsYAP1 protein, humanAdaptor Proteins, Signal TransducingTranscription Factors

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, Anhui Medical University; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Centre of Anti-Inflammatory and Immune Medicin…
  • School of Nursing, Anhui Medical University, Hefei, Anhui, P. R. China.
  • Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.

ORCID-Profile: Huan Qiu

Förderung

  • National Natural Science Foundation of China Youth Project
  • Basic and Clinical Collaboration Enhancement Program of Anhui Medical University
  • The Research Program for Higher Education Institutions in Anhui Province

Zitieren

APA

Jiang, J., Ye, P., Sun, N., Zhu, W., Yang, M., Yu, M., Yu, J., Zhang, H., Gao, Z., Zhang, N., Guo, S., Ji, Y., Li, S., Zhang, C., Miao, S., Chai, M., Liu, W., An, Y., Hong, J., …, & Qiu, H. (2024). Yap methylation‐induced FGL1 expression suppresses anti‐tumor immunity and promotes tumor progression in KRAS ‐driven lung adenocarcinoma. Cancer Communications. https://doi.org/10.1002/cac2.12609

Vancouver

Jiang J, Ye P, Sun N, Zhu W, Yang M, Yu M, et al. Yap methylation‐induced FGL1 expression suppresses anti‐tumor immunity and promotes tumor progression in KRAS ‐driven lung adenocarcinoma. Cancer Communications. 2024. doi:10.1002/cac2.12609

BibTeX
@article{Jiang2024,
  author = {Jiang, Ji and Ye, Pengfei and Sun, Ningning and Zhu, Weihua and Yang, Mei and Yu, Manman and Yu, Jingjing and Zhang, Hui and Gao, Zijie and Zhang, Ningjie and Guo, Shijie and Ji, Yuru and Li, Siqi and Zhang, Cuncun and Miao, Sainan and Chai, Mengqi and Liu, Wenmin and An, Yue and Hong, Jian and Wei, Wei and Zhang, Shihao and Qiu, Huan},
  title = {Yap methylation‐induced FGL1 expression suppresses anti‐tumor immunity and promotes tumor progression in KRAS ‐driven lung adenocarcinoma},
  journal = {Cancer Communications},
  year = {2024},
  doi = {10.1002/cac2.12609}
}
Kostenlos starten →